

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on 20th June 2023.
I am pleased to confirm the following.

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)~22
Abemaciclib + Fulvestrant~3
Alpelisib + Fulvestrant~1
Anthracycline (e.g. doxorubicin or epirubicin) as a single agent~0
Atezolizumab +Nab-paclitaxel/Paclitaxel~1
Capecitabine as a single agent~12
Eribulin as a single agent or in combination~2
Everolimus + Exemestane~0
Fulvestrant as a single agent~0
Lapatinib~0
Neratinib~0
Parp Inhibitors (Olaparib/Talazoparib)~0
Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)~ 8
Palbociclib + Fulvestrant~1
Pembrolizumab~2
Platinum (e.g. carboplatin or cisplatin) as a single agent~
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)~26
Ribociclib + Fulvestrant~13
Sacituzumab Govitecan~0
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent ~9
Taxane and/or Anthracycline in combination~16
Trastuzumab as a single agent or in combination~22
Trastuzumab emtansine~3
Transtuzumab deruxtecan~0
Any other active systemic anti-cancer therapy Pertuzumab / Trastuzumab? 33

Q2. Does your trust participate in any clinical trials for the treatment of breast cancer? If so, please provide the name of each trial and the number of patients taking part.

ATNEC – A randomised trial investigating the requirement for axillary treatment, after chemotherapy, for patients with early-stage breast cancer. **9 patients recruited.**

OPTIMA - Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis. **22 patients recruited.**

POETIC-A - Pre-Operative Endocrine Therapy for Individualised Care with Abemaciclib. No patients recruited yet, 2 potentials approached, waiting for some investigations before consent.

Observational trials: MARECA (9 **patients recruited**) , IMPARTER 4 (PIC trial) **2 patients recruited**

You are advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom of Information Co-ordinator
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the
'Re-use of Public Sector Information Regulations' and best practice.